28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05486481 (ClinicalTrials.gov)	April 1, 2023	1/8/2022	Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation ( ...	A Multicenter Phase 1/2 Study of Venetoclax/ Daratumumab / Dexamethasone for Previously Treated Syst ...	AL Amyloidosis;Light Chain (AL) Amyloidosis;Systemic Light Chain Disease	Drug: Venetoclax;Drug: Dexamethasone;Drug: Daratumumab	Sandy Wong, MD	Janssen Pharmaceuticals;AbbVie	Not yet recruiting	18 Years	N/A	All	78	Phase 1/Phase 2	United States
2	NCT05451771 (ClinicalTrials.gov)	October 26, 2022	6/7/2022	Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Sy ...	AL Amyloidosis	Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: Dex ...	Rajshekhar Chakraborty, MD	Genentech, Inc.	Recruiting	18 Years	N/A	All	53	Phase 1/Phase 2	United States
3	NCT03000660 (ClinicalTrials.gov)	January 2017	12/12/2016	Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis	A Phase I Trial of Venetoclax(ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyl ...	AL Amyloidosis	Drug: Venetoclax;Drug: Dexamethasone	Tufts Medical Center	NULL	Terminated	18 Years	N/A	All	3	Phase 1	United States

First Previous1Next Last